Text Size

Changes in ocular signs and symptoms in patients switching from bimatoprost-Timolol to tafluprost-Timolol eye drops: An open-label phase IV study

Bourne R.R.A., Kaarniranta K., Lorenz K., Traverso C.E., Vuorinen J., Ropo A.


  • 2019
  • BMJ Open
View publication
  • Therapeutic Area

    Glaucoma

  • Categories

    Clinical development

  • Affiliations

    Cambridge University Hospitals, Cambridge, United Kingdom; Vision and Eye Research Unit, Anglia Ruskin University, Cambridge, United Kingdom; Department of Ophthalmology, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland; Department of Ophthalmology, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany; Clinica Oculistica Di.N.O.G.M.I., Università di Genova, Ospedale Policlinico San Martino, Genova, Italy; 4Pharma Ltd, Turku, Finland; Global Medical Affairs, Santen Oy, Helsinki, Finland

Related Publications

An Exploratory Study of Machine Learning-Based Open-Angle Glaucoma Detection Using Specific Autoantibodies

Takada N., Ishikawa M., Ninomiya T., Izumi Y., Sato K., Kunikata H., Yokoyama Y., Tsuda S., Fukuda E., Yamaguchi K., Ono C., Kirihara T., Shintani C., Hanyuda A., Goshima N., Zorumski C.F., NakazawaT.


Relaxation of Precontracted Ciliary Artery and Ciliary Muscle In Vitro by Kinin Peptides: Relevance to Retinal Blood Flow and Intraocular Pressure Regulation

Sharif N.A., Kulkarni-Chitnis M., Okolie A., Chaudhry S.D., Njie-Mbye Y.F., Ohia S.E.


The Role of EP3 Agonism in Intraocular Pressure-Lowering by Sepetaprost, a Novel Dual Agonist of FP and EP3 Receptors, in Monkeys

Maki K., Kimura E., Yamamoto Y., Fuwa M., Toris C.B., Fan S., Shimazaki A., Kato M.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022